Vrije Universiteit Brussel
- Address
- lock Available on a paid plan
Neoplasms and Hematology Research
At Vrije Universiteit Brussel in Jette, clinical trials in neoplasms focus on blood cancers and related malignancies, including prostate cancer, multiple myeloma, and a range of hematological malignancies such as AML, MDS, CML, and lymphoma. The studies are designed to assess treatment effectiveness, compare therapeutic options, and monitor longer-term safety in patients who may continue to benefit from ongoing care.
- Evaluating new and existing treatments for prostate cancer and multiple myeloma
- Comparing approaches for relapsed/refractory multiple myeloma
- Supporting treatment decisions in hematological cancers with a focus on safety and benefit
These trials reflect a strong focus on improving outcomes for patients with complex cancers while helping clarify which therapies offer the most durable benefit.
Immune System Diseases and Rheumatology Studies
Research in immune system diseases includes clinical trials for rheumatoid arthritis, where investigators are testing strategies to improve disease control and long-term patient outcomes. The work centers on reducing inflammation, improving remission rates, and understanding how treatment choices affect the course of disease over time.
- Studying treatment strategies for early rheumatoid arthritis
- Comparing approaches that aim to improve remission and reduce disease burden
- Following patients over time to assess safety and lasting effectiveness
This area highlights a practical effort to refine care for chronic inflammatory disease using evidence from both treatment and follow-up studies.
Metabolism and Endocrinology Trials
The site also conducts research in metabolism, with studies in type 1 diabetes mellitus aimed at preserving pancreatic beta-cell function and improving understanding of disease progression. These trials are intended to test whether a therapy can help maintain natural insulin production after diagnosis.
- Investigating ways to preserve beta-cell function in newly diagnosed type 1 diabetes
- Measuring changes in insulin-related responses over time
- Exploring treatments that may slow early disease progression
This research supports better care for people with diabetes by focusing on early intervention and disease preservation.
Musculoskeletal Diseases and Age-Related Function
In the area of musculoskeletal diseases, trials at the Vrije Universiteit Brussel examine sarcopenia and related loss of mobility in older adults. The goal is to evaluate whether treatment can help maintain physical function and reduce the risk of disability.
- Studying therapies for sarcopenia in older patients
- Assessing ways to prevent or delay major mobility disability
- Focusing on quality of life and independence in aging populations
These studies address an important challenge in aging care by examining treatments that may support strength, movement, and daily functioning.
Transplantation and Supportive Hematology Research
The hematology department also contributes to trials in allogeneic hematopoietic cell transplantation, comparing conditioning approaches for patients receiving donor transplants. This research is aimed at improving transplant success and long-term disease control while balancing safety and recovery.
- Comparing conditioning strategies for allogeneic stem cell transplantation
- Seeking better outcomes after transplant for blood cancers
- Evaluating treatment regimens that may improve survival and disease-free recovery
By studying transplant preparation and outcomes, the site supports advances in care for patients with serious blood disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 31 therapeutic areas and 15 of 393 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 370 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 75 by active trials.
- 1UZ Brussel18active
lock +74 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1UZ Brussel23trials
lock +43 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vrije Universiteit Brussel
lock Showing 1 of 267 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 393 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 19 | Unknown | 2018-08-24 | 2025-12-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
